Stories about: diagnostics

Six technologies we backed in 2017

Boston Children's Hospital technology

Boston Children’s Hospital’s Technology Development Fund (TDF) to designed to transform early-stage academic technologies into validated, high-impact opportunities for licensees and investors. Since 2009, the hospital has committed $7.6 million to support 76 promising technologies, from therapeutics, diagnostics, medical devices and vaccines to regenerative medicine and healthcare IT projects. The TDF also assists with strategic planning, intellectual property protection, regulatory requirements and business models. Investigators can access mentors, product development experts and technical support through a network of contract research organizations, development partners and industry advisors.

Eight startup companies have spun out since TDF’s creation, receiving $82.4 million in seed funding. They include Affinivax, a vaccine company started with $4 million from the Gates Foundation, and Epidemico, a population health-tracking company acquired by Booz Allen Hamilton. TDF has also launched more than 20 partnerships, received $26 million in follow-on government and foundation funding and generated $4.45 million in licensing revenue.

Here are the projects TDF awarded in 2017, with grants totaling $650,000:

Read Full Story | Leave a Comment

Crunching the autism equation in the DSM-5 era

solving the autism equation
An 'Information Commons' could better delineate the different faces of ASD by combining objective molecular, biochemical and neurological measures.
Alal Eran, PhD, studies the molecular basis of autism at Boston Children’s Hospital and Harvard Medical School.

Yet another redefinition of autism spectrum disorder (ASD) has stirred up debate. The new Diagnostic and Statistical Manual of Mental Disorders (DSM-5) now collapses four previously distinct conditions—autistic disorder, Asperger syndrome, childhood disintegrative disorder and pervasive developmental disorder not otherwise specified—under one umbrella label of ASD. It also collapses the traditional autistic triad (social deficits, communication impairments and restricted interests/behaviors) into two domains: social/communication deficits and restricted interests/behaviors.

While intended to increase accuracy and utility, the new diagnostic criteria for autism—the fifth revision since 1980—have attracted an unprecedented level of criticism by clinicians, researchers and families. The criteria for membership in DSM categories are much less robust than those for other clinical classification schemes—as evidenced by the rapid change in the DSM over the last 50 years. But more importantly, they are based only on behavioral symptoms.

Read Full Story | Leave a Comment

What’s going around: Can biosurveillance data improve patient care in real-time?

A broad view of what's going on locally may help doctors make better clinical decisions when patients come to them for things like strep throat. (zigazou76/Flickr)

Anyone’s risk of catching an infectious disease is closely linked to what epidemiologists call the disease’s incidence: the number of people in a given area infected with that disease in a given time period. We often have a kind of water-cooler-level awareness about incidence, saying things like, “I hear there’s something going around,” or “Half of my son’s class was out with something last week,” while talking to co-workers or friends about our sniffle or our child’s stomach bug.

Kenneth Mandl and Andrew Fine, in the Children’s Hospital Informatics Program, want to take this awareness a step further by collecting real-time population-level biosurveillance information and packaging it for doctors, like your primary care doctor or your child’s pediatrician. Right now, doctors rarely have access to this kind of data, and even if they do, they have few recognized methods at their disposal for formally making use of the data in their clinical decision making processes.

Read Full Story | Leave a Comment

Ideas fly at Proteomics 2011

“What is proteomics?” Answering this simple question was the motivation for the Proteomics 2011, an annual symposium hosted by Judith and Hanno Steen of the Steen & Steen lab and The Proteomics Center at Children’s, featuring global innovators and local advances in proteomics at Children’s Hospital Boston, held last week. As a video at the start of the symposium showed, it’s a question that elicits a wide range of answers:

Video courtesy of the Carino Agency.

Read Full Story | Leave a Comment